
Calibr-Skaggs announces initial dosing of a first-in-class regenerative lung medicine in a phase 1 trial for idiopathic pulmonary fibrosis CMR316 is a once-weekly inhaled, lung-targeted drug designed to precisely expand lung stem cells and regenerate damaged lung tissue.
October 30, 2024
LA JOLLA, CA The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development division of Scripps Research, announced today that the first dose of a pioneering regenerative lung therapy, CMR316, has been given in a phase 1 trial assessing safety and tolerability in healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF). This once-weekly, inhaled drug has potential to revolutionize treatment of lung diseases by stimulating stem cells to regenerate damaged lung tissue.
There are currently no regenerative treatments for any lung disease, including IPF, which is a deadly condition characterized by extensive tissue damage and permanent lung scarring, says Chan Beals, MD, chief medical officer of Calibr-Skaggs. Based on our encouraging preclinical data, CMR316 has the potential to halt or even reverse IPF, in addition to other severe lung conditions such as chronic obstructive pulmonary disease. This clinical milestone achieved through the collaborative bench to bedside' model of Scripps Research and Calibr-Skaggs scientists brings us closer to delivering a first-in-class medicine that could transform the lives of many people affected by debilitating lung diseases.
IPF is a severe, chronic, and progressive disease with no known cause and no cure. It affects roughly 100,000 people in the United States, drastically reducing their quality of life. With ever-increasing fibrosis in the lung over time, IPF progresses from mild shortness of breath and dry cough during activity to an inability to breathe even at rest. Difficulty breathing can lead to pulmonary hypertension and respiratory failure, preventing the brain and other organs from receiving adequate oxygen. There is no cure for IPF, aside from a lung transplant which is rarely an option, and tragically, patient survival after diagnosis is a mere 2 5 years. Available treatments, such as anti-fibrotics, can only slow disease progression and manage symptoms, highlighting the critical need for innovative new therapies. With an understanding that the lung's natural yet limited capacity to regenerate and repair is impaired in IPF, a new therapeutic strategy has emerged.
CMR316 is a first-in-class drug designed to precisely stimulate lung stem cells to regenerate lung tissue. Specifically, CMR316 targets type 2 alveolar epithelial cells (AEC2s) the stem cells in the lower airway of the lungs that are reduced in patients with IPF. Stimulating AEC2 stem cells causes them to differentiate into type 1 AEC (AEC1) cells that are crucial for gas exchange and maintaining lung stability and function. Thus, stimulating AEC2 stem cells with CMR316 has potential to repair damage caused by many lung conditions, including IPF. Furthermore, CMR316's regenerative mechanism is distinct yet complementary to that of approved anti-fibrotics, which could allow them to be combined for even greater effect.
CMR316 was discovered and developed through a partnership between Scripps Research and Calibr-Skaggs scientists, led by President and CEO Peter Schultz, PhD, and Associate Professor of Chemistry Michael Bollong, PhD, who is the Early Endowed Roon Chair for Cardiovascular Research. In April 2024, they published a study in the Proceedings of the National Academy of Sciences, which provided proof of concept for CMR316's ability to stimulate AEC2s to regenerate lung tissue in IPF and several other lung disease models.
From this foundational bench' research, the Calibr-Skaggs drug development team, led by Vice President of Pharmacology Sean Joseph, PhD, performed critical preclinical safety studies and received regulatory approval to reach the bedside' for testing CMR316 in humans.
Through careful testing of CMR316 over the last few years a huge team effort we are cautiously optimistic that the benefits and exceptional safety profile we observed preclinically will translate to patients with lung diseases, including those with IPF, says Joseph.
CMR316 is being tested at Fraunhofer ITEM in Hanover, Germany in an extensive phase 1 study in healthy volunteers (Parts 1 and 2) and patients with IPF (Part 3). The study title is A Phase 1/1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Nebulized CMR316 in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis (EU trial number: 2023-510456-23-00). The main objective of the trial is to assess the safety and tolerability of single (Part 1) and multiple inhaled doses of CMR316 in healthy volunteers (Part 2) and patients with IPF (Part 3).
This work was supported by funding from Calibr-Skaggs, with additional support from the Bachrach Family Foundation.
Calibr-Skaggs Schultz, Peter Bollong, Michael
Most recent headlines
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
17/11/2026
Fabric Insights and Fonn Group have announced a partnership to connect editorial...
17/11/2026
The National Association of Black Journalists is offering up a Thanksgiving Eve treat on Wednesday, Nov. 25, in the form of a live streaming event featuring for...
17/11/2026
Bridge Technologies has announced that its VB440 production probe now supports both monitoring and signal generation for Apple ProRes video streams. The additio...
17/11/2026
Canon U.S.A., Inc. recently welcomed 21 Jericho High School students to its Melv...
17/11/2026
Spectrum News has deployed the Amagi platform to support its live news operations. Amagi says the platform lets Spectrum News streamline newsroom workflows, red...
17/11/2026
Microsoft has expanded its use of Haivision's live video contribution ecosys...
17/11/2026
Setanta Sports has deployed Ateme's TITAN Live platform to support its OTT video delivery operations. Ateme's transcoding technology is integrated into ...
17/11/2026
Media Links has joined the KAIROS Alliance Partner program for Panasonic's KAIROS IT/IP live video production platform. The company completed interoperabili...
17/11/2026
Behind The Mic provides a roundup of recent news regarding on-air talent, including new deals, departures, and assignments compiled from press releases and repo...
17/11/2026
In live sports and in life, things go by in the blink of an eye. Savoring the mo...
17/11/2026
Satellite operators are adding a new generation of low-Earth-orbit (LEO) network...
17/11/2026
Clear-Com has delivered five customized test systems for electromagnetic securit...
17/11/2026
Stephen Arnold Music (SAM) has created the sonic identity for WTGL, the women's team golf league from TMRW Sports, created in partnership with the LPGA and ...
17/11/2026
The Professional Audio Manufacturers Alliance (PAMA) has introduced Give Sound a Voice, an initiative aimed at raising awareness of the value of sound among the...
17/11/2026
Fanatics Studios, the sports entertainment joint venture between Fanatics and OBB, has named Jamal Henderson its first President of Film & TV, announced Michael...
17/11/2026
The NFL's Thanksgiving Week games will feature halftime performances by U2, ...
17/11/2026
FanSided, a Minute brand with more than 250 fan communities, has launched a redesigned mobile app that combines team news, analysis, live game coverage, stats a...
17/11/2026
Major League Volleyball (MLV), the longest-running indoor professional volleybal...
17/11/2026
Prime Video will present a 15-hour slate of live sports on Black Friday, Nov. 27...
17/11/2026
Catherine Dior was more than a muse. A Resistance fighter, a survivor of deporta...
17/11/2026
Multiband dynamics plug-in boasts FT1 integration
Freqport's latest plug-in combines multiband upward and downward dynamics with the company's renow...
17/11/2026
Hi-fi experts launch two pro-audio models
Berlin-based hi-fi experts Teufel Audio have recently branched out into the pro-audio world with their first pairs...
17/11/2026
A year of ComposerCloud+ for $99
EastWest's annual Black Friday Sale is already live, and new users are being offered one year of the all-encompassing C...
17/11/2026
Pick your favourite gear from 2026
The annual SOS Awards are now underway, and as always, we're asking readers to help us choose the best pro-audio rele...
17/11/2026
As part of an ongoing series production program for a German automaker, production capacity has been increased at SGL Carbon's Austrian site in Ried im Innk...
17/11/2026
eds3_5_jq(document).ready(function($) { $(#eds_sliderM519).chameleonSlider_2_1({...
17/11/2026
Signiant has acquired the media intelligence technology, Ceivo, developed by Burnlab with founder Aaron Sloman joining the company as Vice President, Product Ma...
17/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
17/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
17/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
17/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
17/11/2026
Berklees 2027 Alumni Grammy Nominees: See the Full List From pop and R&B to jazz, musical theater, and video game scores, Berklee talent is represented across...
17/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
17/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
17/11/2026
LA JOLLA, CA-Two Scripps Research faculty, Assistant Professor Christian Diercks...
17/11/2026
Our Biggest Sale of the Year on Ivory 3!
From November 17th through November 30th, enjoy our best savings of the year on Ivory 3 Products!
Whether it's ou...
17/11/2026
Tuesday 17 November 2026
Sky announces major free upgrade to the Sky Glass and ...
17/11/2026
Tuesday 17 November 2026
Passion, Betrayal and Scandal: Sky Arts Reveals the Ma...
17/11/2026
Exact 3D Video, a web service based in Japan, has launched its English version, ...
17/11/2026
Today, Apple Podcasts named Baby, this is Keke Palmer its Show of the Year, hono...
17/11/2026
NVIDIA's Ian Buck kicked off the company's week at SC26 in Chicago on Monday with new tools for AI agents, software that can plan experiments, run code ...
16/11/2026
The ESPN Edge Innovation Conference once again gave key ESPN technology partners as a chance to take to the stage and discuss the future of sports fan experienc...
16/11/2026
As rights holders rethink who tells their stories and where, IMG is preparing th...
16/11/2026
From the sidelines, sonic savants advocate for greater emphasis on sound as sports and entertainment increasingly merge
SVG Live!, a one-day event on Nov. 10 i...
16/11/2026
Deal combines Yamaha's audio technology with Disguise's visual-productio...
16/11/2026
Creative effects designed to encourage experimentation
Berry Effects is the brainchild of Abe and Ralph, a pair of multi-instrumentalists and audio engineer...
16/11/2026
Physics-based synth gets first major update
Anukari have just released a new version of their innovative physics-based software synth, marking the instrumen...
16/11/2026
Both versions kitted out with new tools & improvements
Hit'n'Mix have just launched the latest major version of their innovative DAW software, with ...
16/11/2026
Dynamic bands, unmasking features & new stereo tools
Launched in 2021, Eventide's SplitEQ plug-in introduced an interesting new approach to EQ, with the...